|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
30th November, 2005
GlaxoSmithKline presents rapidly expanding pipeline of oncology and supportive care compounds
GlaxoSmithKline presents rapidly expanding pipeline of oncology and supportive care compounds
Issued — Wednesday 30th November 2005
Philadelphia, PA, London, UK, November 30, 2005 — GlaxoSmithKline plc [NYSE:GSK] today updated investors and financial analysts in New York on the Company’s rapidly expanding pipeline featuring innovative science that addresses a broad range of patient needs for cancer prevention, treatment and supportive care ...
|
30th November, 2005
Number of pills affects adherence to HIV treatment regimens
Number of pills affects adherence to HIV treatment regimens
Patients Taking Combination Pills Three Times More Likely to Refill Prescriptions on Time
Research Triangle Park, NC – November 30, 2005 – Fixed-dose combination therapies for HIV may increase the likelihood of treatment adherence among patients, according to a recently published study of 2,112 patients conducted by GlaxoSmithKline ...
|
28th November, 2005
GlaxoSmithKline Biologicals licenses Institut Pasteur technology to develop AIDS vaccine; innovative public-private partnership will use measles vaccine as starting point
GlaxoSmithKline Biologicals licenses Institut Pasteur technology to develop AIDS vaccine; innovative public-private partnership will use measles vaccine as starting point
Paris - 28 November 2005 - EU-funded project will develop vaccine with academic collaborators in France, Belgium, and the United Kingdom
PARIS—Using an ancient scourge to combat a new one, researchers from GlaxoSmithKline Biologicals and the Institut Pasteur announced a new European collaboration to develop an AIDS vaccine by fusing genes from the human immunodeficiency virus (HIV) onto an existing measles vaccine ...
|
25th November, 2005
£470,000 in research awards to aid medical advance into chronic diseases
£470,000 in research awards to aid medical advance into chronic diseases
London, November 25, 2005 - Four medical research projects making impressive advances into the cause, diagnosis, and treatment of life-threatening diseases have been awarded in total over £470,000 by GlaxoSmithKline in their annual medical research awards programme ...
|
24th November, 2005
GlaxoSmithKline announces Hycamtin® receives positive opinion in Europe for treatment of patients with relapsed small cell lung cancer
GlaxoSmithKline announces Hycamtin® receives positive opinion in Europe for treatment of patients with relapsed small cell lung cancer
Not for distribution to US Media
London – November 24, 2005– GlaxoSmithKline (GSK) today announced that HYCAMTIN® (topotecan powder for concentration for solution for infusion) received positive opinion from the European Committee for Human Medicinal Products (CHMP) for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate ...
|
18th November, 2005
GlaxoSmithKline and Malaria Consortium Announce New Partnership to Expand International Malaria Advocacy
GlaxoSmithKline and Malaria Consortium Announce New Partnership to Expand International Malaria Advocacy
Not for distribution to US Media
3 Year, US$1.5 Million Grant to Support Advocacy in Africaand Europe
Issued – 18th November 2005, 12.00 Cameroon – GlaxoSmithKline’s African Malaria Partnership today announced it will award a grant of £900,000 (US$1.5M) to the Malaria Consortium, an international non-profit organisation dedicated to improving malaria control ...
|
18th November, 2005
GSK statement on FDA proposed labeling change for Serevent and Advair
GSK statement on FDA proposed labeling change for Serevent and Advair
Issued — November 18, 2005 - RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline disagrees with the FDA’s proposed product labeling changes for Serevent and Advair, because they are inconsistent with established NIH treatment guidelines and the standard of care for asthma treatment, which could put many patients at risk of uncontrolled asthma ...
|
18th November, 2005
FDA approves updated labeling for GSK’s LEXIVA
FDA approves updated labeling for GSK’s LEXIVA
Co-administration With Esomeprazole Does Not Affect Blood Levels of LEXIVA
Research Triangle Park, NC - November 18, 2005 - GlaxoSmithKline (NYSE: GSK) today announced that the U.S ...
|
17th November, 2005
The University of Oxford and GlaxoSmithKline To Collaborate In Cancer Research At Leading Clinical Centres In India
The University of Oxford and GlaxoSmithKline To Collaborate In Cancer Research At Leading Clinical Centres In India
Issued — 17th November 2005, 12.00 GMT, London - The University of Oxford and GlaxoSmithKline (GSK) today announced a new collaboration in cancer research to be conducted through leading clinical centres in India ...
|
17th November, 2005
GSK donates 350,000 doses of Hepatitis-A vaccine for children in Pakistan disaster relief camps
GSK donates 350,000 doses of Hepatitis-A vaccine for children in Pakistan disaster relief camps
London, 17th November 2005: GlaxoSmithKline announced today that it will donate up to 350,000 doses of hepatitis-A vaccine for children, Havrix JuniorTM to the health authorities in Pakistanfor use in the relief camps housing those affected by the recent earthquake ...
|
|
|
|
« Previous 10 Next 10 » |
|
|
|
|
